In a head-to-head clinical trial, researchers studied progression-free survival (PFS) in 361 patients taking INLYTA versus 362 patients taking Nexavar® (sorafenib). Progression-free survival is the length of time during and after cancer treatment that a patient lives without the disease worsening. This is one way to check how effective it is. The study showed that:
INLYTA extended median PFS by 43% compared to Nexavar |
43% |
Patients taking INLYTA experienced a median PFS of 6.7 months compared with 4.7 months for those taking Nexavar. That’s a 2-month increase in median PFS. |
INLYTA also decreased the overall risk of disease progression by 33% compared to Nexavar |
33% |
Disease progression includes tumor growth, tumor spread, and death. |
2 x |
70 of 361 patients taking INLYTA saw their tumors shrink compared to 34 of 362 patients taking Nexavar. This includes patients whose tumors shrank 30% or more and whose response to treatment lasted at least 4 weeks. |
Along with progression-free survival, this study also measured overall survival. This is the total time patients on each medicine remained alive after starting treatment. There was no significant difference in overall survival between the patients taking INLYTA and the patients taking Nexavar.
INLYTA is not a cure. The data represent an average, and not all patients will experience the same results.
Nexavar is a registered trademark of Bayer Pharmaceuticals Corporation.
Read Important Safety Information for INLYTA. |
|
Before taking INLYTA, tell your healthcare provider about all of your medical conditions, including if you:
For females, tell your healthcare provider if you:
For males with female partners who are able to become pregnant:
INLYTA may cause fertility problems in males and females, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INLYTA and certain other medicines can affect each other causing serious side effects.
Talk with your healthcare provider before you start taking any new medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Do not drink grapefruit juice or eat grapefruit. Grapefruit may increase the amount of INLYTA in your blood.
INLYTA may cause serious side effects, including:
The most common side effects of INLYTA with pembrolizumab include:
Important information: If your healthcare provider prescribes INLYTA for you to be taken with pembrolizumab, also read the Medication Guide for pembrolizumab.
The most common side effects of INLYTA when used alone include:
These are not all of the possible side effects of INLYTA. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see full Prescribing Information and Patient Information, which includes a complete discussion of the risks of INLYTA.
INLYTA is a prescription medicine used to treat kidney cancer that has spread or cannot be removed by surgery (advanced renal cell carcinoma or RCC):
It is not known if INLYTA is safe and effective in children.
INLYTA is a prescription medicine used to treat kidney cancer that has spread or cannot be removed by surgery (advanced renal cell carcinoma or RCC):
It is not known if INLYTA is safe and effective in children.
A mass of cancer cells.
A disease of the arteries (commonly called high blood pressure).
Located throughout the body, lymph nodes filter lymph fluid. They store special cells that can trap cancer cells or bacteria that are traveling through the body in the lymph.
One of a pair of organs that removes waste products from the blood. In the process, they make urine to help carry waste products out of the body. One is on the left side of the abdomen. The other is on the right side.
INLYTA (axitinib) is a prescription medicine used to treat kidney cancer that has spread or cannot be removed by surgery (advanced renal cell carcinoma or RCC):
It is not known if INLYTA is safe and effective in children.
Cancer that has spread from one part of the body to another through the lymphatic system or bloodstream.